NAYA Biosciences, Inc.
NAYA · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -0.00 | -0.08 |
| FCF Yield | -575.08% | -23.14% | -23.23% | -4.19% |
| EV / EBITDA | -0.51 | -3.78 | -6.95 | -24.64 |
| Quality | ||||
| ROIC | -91.72% | -11.16% | -12.61% | -16.21% |
| Gross Margin | 36.18% | 43.21% | 31.03% | 53.08% |
| Cash Conversion Ratio | 0.20 | 0.17 | 0.39 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 87.04% | 99.54% | 20.13% | 17.29% |
| Free Cash Flow Growth | -411.33% | -8.65% | 57.58% | -386.95% |
| Safety | ||||
| Net Debt / EBITDA | -0.47 | -2.85 | -4.43 | -2.69 |
| Interest Coverage | -54.96 | -17.15 | -4.75 | -5.15 |
| Efficiency | ||||
| Inventory Turnover | 4.83 | 4.36 | 4.09 | 3.45 |
| Cash Conversion Cycle | -383.99 | -507.13 | -203.61 | 38.72 |